KR102236259B1 - 항-lag-3 항체 및 그것의 사용 - Google Patents

항-lag-3 항체 및 그것의 사용 Download PDF

Info

Publication number
KR102236259B1
KR102236259B1 KR1020197014275A KR20197014275A KR102236259B1 KR 102236259 B1 KR102236259 B1 KR 102236259B1 KR 1020197014275 A KR1020197014275 A KR 1020197014275A KR 20197014275 A KR20197014275 A KR 20197014275A KR 102236259 B1 KR102236259 B1 KR 102236259B1
Authority
KR
South Korea
Prior art keywords
antibody
seq
lag
cancer
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197014275A
Other languages
English (en)
Korean (ko)
Other versions
KR20190111894A (ko
Inventor
레이 팡
젱이 왕
빙시 궈
징우 장
웬칭 지앙
용치앙 왕
Original Assignee
아이-맵 바이오파마 유에스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CN2017/074365 external-priority patent/WO2018152687A1/en
Application filed by 아이-맵 바이오파마 유에스 리미티드 filed Critical 아이-맵 바이오파마 유에스 리미티드
Publication of KR20190111894A publication Critical patent/KR20190111894A/ko
Application granted granted Critical
Publication of KR102236259B1 publication Critical patent/KR102236259B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Rheumatology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Pathology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
KR1020197014275A 2017-02-22 2018-02-22 항-lag-3 항체 및 그것의 사용 Active KR102236259B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/CN2017/074365 WO2018152687A1 (en) 2017-02-22 2017-02-22 Anti-lymphocyte activation gene-3 (lag-3) antibodies and uses thereof
CNPCT/CN2017/074365 2017-02-22
CN2017088570 2017-06-16
CNPCT/CN2017/088570 2017-06-16
PCT/CN2018/076940 WO2018153340A1 (en) 2017-02-22 2018-02-22 Anti-lag-3 antibodies and uses thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020187022954A Division KR102144317B1 (ko) 2017-02-22 2018-02-22 항-lag-3 항체 및 그것의 사용

Publications (2)

Publication Number Publication Date
KR20190111894A KR20190111894A (ko) 2019-10-02
KR102236259B1 true KR102236259B1 (ko) 2021-04-06

Family

ID=63253327

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020187022954A Active KR102144317B1 (ko) 2017-02-22 2018-02-22 항-lag-3 항체 및 그것의 사용
KR1020197014275A Active KR102236259B1 (ko) 2017-02-22 2018-02-22 항-lag-3 항체 및 그것의 사용

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020187022954A Active KR102144317B1 (ko) 2017-02-22 2018-02-22 항-lag-3 항체 및 그것의 사용

Country Status (12)

Country Link
US (2) US10577421B2 (enExample)
EP (1) EP3389702A4 (enExample)
JP (1) JP6929951B2 (enExample)
KR (2) KR102144317B1 (enExample)
CN (1) CN109475617B (enExample)
AU (1) AU2018226298B2 (enExample)
CA (1) CA3053989C (enExample)
IL (1) IL268734A (enExample)
NZ (1) NZ756678A (enExample)
SG (1) SG11201907561PA (enExample)
WO (1) WO2018153340A1 (enExample)
ZA (1) ZA201905790B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI875679B (zh) 2017-07-06 2025-03-11 荷蘭商米樂斯股份有限公司 藉由細胞表現之調控生物活性的抗體
CN110678484B (zh) * 2018-08-21 2022-12-27 天境生物科技(杭州)有限公司 抗pd-l1/抗lag3双特异性抗体及其用途
EP3833693A4 (en) * 2018-08-21 2023-06-07 ABL Bio Inc. Anti-pd-l1/anti-lag3 bispecific antibodies and uses thereof
CN110066334B (zh) * 2019-03-22 2020-03-10 南京医科大学 抗Galectin-3的全人源化单域抗体及应用
CN112010976B (zh) * 2019-05-29 2022-07-01 山东博安生物技术股份有限公司 抗lag3抗体及其用途
CN110320367A (zh) * 2019-05-30 2019-10-11 广州医科大学附属第一医院（广州呼吸中心） 基于lag-3的诊断试剂盒及其在帕金森病诊断产品上的应用
KR102444797B1 (ko) * 2019-06-14 2022-09-20 에이비엘바이오 주식회사 α-SYN/IGF1R에 대한 이중 특이 항체 및 그 용도
CN112513097B (zh) * 2019-07-11 2021-10-29 武汉友芝友生物制药有限公司 四价对称双特异性抗体
EP4039711A4 (en) * 2019-07-23 2023-11-15 Nanjing GenScript Biotech Co., Ltd. BISPECIFIC ANTI-CD47/ANTI-LAG-3 ANTIBODY, PREPARATION METHOD AND USE THEREOF
CN113004407B (zh) * 2019-12-20 2022-11-11 广东菲鹏制药股份有限公司 Lag3抗体及其应用
CN113348182B (zh) * 2019-12-30 2022-07-12 上海海路生物技术有限公司 Lag-3抗体及其医药用途
WO2021163989A1 (en) * 2020-02-21 2021-08-26 Yinnuolai Biotech Ltd. Anti-baff receptor antibodies and uses thereof
CN116023484A (zh) * 2020-05-19 2023-04-28 益科思特(北京)医药科技发展有限公司 抗新型冠状病毒Spike蛋白抗体及其应用
CN114605544B (zh) * 2020-06-05 2023-08-01 北京天广实生物技术股份有限公司 Lag3抗体及其用途
CN112062832B (zh) * 2020-09-24 2021-08-03 河南赛诺特生物技术有限公司 Galectin-3抗原表位肽、抗原、抗体、杂交瘤细胞株及试剂盒
CN114621345B (zh) * 2020-12-10 2022-11-29 北京东方百泰生物科技股份有限公司 一种抗lag-3的单克隆抗体、其抗原结合片段及其应用
CA3209479A1 (en) 2021-02-03 2022-08-11 Mozart Therapeutics, Inc. Binding agents and methods of using the same
CN115490764B (zh) * 2021-06-18 2025-06-03 佛山热休生物技术有限公司 Lgals3的表位肽及所述表位肽与热休克蛋白的复合物
WO2023076876A1 (en) 2021-10-26 2023-05-04 Mozart Therapeutics, Inc. Modulation of immune responses to viral vectors
US20250198990A1 (en) * 2022-03-15 2025-06-19 The Board Of Trustees Of The Leland Stanford Junior University Methods of Identifying Anti-LAG-3 Agents
CN115819595B (zh) * 2023-01-03 2023-05-16 上海百英生物科技股份有限公司 一种抗lag3纳米抗体及其制备方法与应用
WO2024189628A1 (en) * 2023-03-16 2024-09-19 Technion Research And Development Foundation Limited Lag-3 inhibition for enhanced antiviral immune response
WO2024196072A1 (ko) * 2023-03-20 2024-09-26 경북대학교 산학협력단 Lag-3에 결합하는 펩타이드 및 이의 용도
WO2025040080A1 (en) * 2023-08-21 2025-02-27 Beigene Switzerland Gmbh Treatment of esophageal cancer with anti-lag3, anti-pd-1 and chemotherapy
US20250197493A1 (en) * 2023-12-13 2025-06-19 Eli Lilly And Company Lag-3 agonist antibodies

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR072999A1 (es) * 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
UY34887A (es) * 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
MY210104A (en) * 2013-03-15 2025-08-27 Glaxosmithkline Ip Dev Ltd Anti-lag-3 binding proteins
CN106029694A (zh) * 2013-12-06 2016-10-12 达纳-法伯癌症研究院公司 治疗性肽
EP3660050A1 (en) * 2014-03-14 2020-06-03 Novartis AG Antibody molecules to lag-3 and uses thereof
JO3663B1 (ar) * 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
MA41463A (fr) * 2015-02-03 2017-12-12 Anaptysbio Inc Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3)
TWI773646B (zh) * 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
TWI733687B (zh) * 2015-07-22 2021-07-21 美商索倫多醫療公司 結合ｌａｇ３之抗體治療劑
SG10202010506TA (en) * 2015-07-30 2020-11-27 Macrogenics Inc Pd-1-binding molecules and methods of use thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Cancer Immunol. Res., 2015, 제3권, 제4호, 페이지 412-423*
Cancer Res., 2014, 제74권, 제13호, 페이지 3418-3428*

Also Published As

Publication number Publication date
US20200071403A1 (en) 2020-03-05
AU2018226298A1 (en) 2019-09-19
CA3053989C (en) 2024-10-29
CN109475617A (zh) 2019-03-15
NZ756678A (en) 2023-02-24
US20190225687A1 (en) 2019-07-25
WO2018153340A1 (en) 2018-08-30
US11414485B2 (en) 2022-08-16
AU2018226298B2 (en) 2022-02-17
IL268734A (en) 2019-10-31
CN109475617B (zh) 2022-05-17
EP3389702A4 (en) 2019-08-14
ZA201905790B (en) 2025-03-26
EP3389702A1 (en) 2018-10-24
KR102144317B1 (ko) 2020-08-18
US10577421B2 (en) 2020-03-03
KR20180113195A (ko) 2018-10-15
KR20190111894A (ko) 2019-10-02
SG11201907561PA (en) 2019-09-27
JP2020508303A (ja) 2020-03-19
JP6929951B2 (ja) 2021-09-01
CA3053989A1 (en) 2018-08-30

Similar Documents

Publication Publication Date Title
KR102236259B1 (ko) 항-lag-3 항체 및 그것의 사용
JP6896989B2 (ja) 抗体結合ｌａｇ−３及びその使用
US20210147538A1 (en) Agonistic antibodies that bind cd40
JP2021509889A (ja) ヒトクローディン−１８．２を結合する抗体およびその使用
JP7493254B2 (ja) Ｐｄ－１結合抗体及びその用途
IL293244A (en) Agonist antibodies against icos and their uses
WO2018152687A1 (en) Anti-lymphocyte activation gene-3 (lag-3) antibodies and uses thereof
US20210095032A1 (en) Antibodies binding pd-1 and uses thereof
CN111989341B (zh) 结合tim-3的抗体及其用途
HK1262681B (en) Anti-lag-3 antibodies and uses thereof
HK1262681A1 (en) Anti-lag-3 antibodies and uses thereof
HK40040207A (en) Antibody binding tim-3 and use thereof

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20190517

Application number text: 1020187022954

Filing date: 20180809

PG1501 Laying open of application
PN2301 Change of applicant

Patent event date: 20200507

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200526

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20200603

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20210106

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20210330

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20210331

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20240228

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20250225

Start annual number: 5

End annual number: 5